Photodynamic Diagnostics and Noninvasive Bladder Cancer: Is It Cost-Effective in Long-Term Application? A Germany-Based Cost Analysis

European Urology

Volumn 52, Issue 1, 2007, Pages 142-147

  Burger, Maximilian ^a   Zaak, Dirk ^b   Stief, Christian G ^b   Filbeck, Thomas ^a   Wieland, Wolf Ferdinand ^a   Roessler, Wolfgang ^a   Denzinger, Stefan ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Aminolaevulinic acid; Bladder cancer; Cost analysis; Photodynamic diagnostic

Indexed keywords

AMINOLEVULINIC ACID; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSURETHRAL RESECTION; WHITE LIGHT;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; COST-BENEFIT ANALYSIS; DIAGNOSTIC TECHNIQUES, UROLOGICAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLUORESCENCE; FOLLOW-UP STUDIES; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOTOSENSITIZING AGENTS; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 34249098357     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.01.064     Document Type: Article

References (19)

1. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 16 (2005) 481-488
2. Botteman M.F., Pashos C.L., Redaelli A., Laskin B., and Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21 (2003) 1315-1330
3. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-475
4. Hedelin H., Holmang S., and Wiman L. The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol 36 (2002) 344-347
5. Lotan Y., Svatek R.S., and Sagalowsky A.I. Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer 107 (2006) 982-990
6. Jakse G., Algaba F., Malmstrom P.U., and Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: Why?. Eur Urol 45 (2004) 539-546
7. Zaak D., Karl A., Knuechel R., et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int 96 (2005) 217-222
8. D'Hallewin M.-A., Bezdetnaya L., and Guillemin F. Fluorescence detection of bladder cancer: a review. Eur Urol 42 (2002) 417-425
9. Filbeck T., Pichlmeier U., Knuechel R., Wieland W.F., and Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 168 (2002) 67-71
10. Filbeck T., Pichlmeier U., Knuechel R., Wieland W.F., and Roessler W. Do patients profit from 5-aminolevulinic acid induced fluorescence diagnosis in transurethral resection of bladder carcinoma?. Urology 60 (2002) 1025-1028
11. Orellana C. Reform in German hospital funding system concerns doctors. Lancet 359 (2002) 328-329
12. Krukemeyer M.G. Structural problems in the German hospital system. Cent Eur J Public Health 12 (2004) 161-165
13. Daniltchenko D.I., Riedl C.R., Sachs M., et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 174 (2005) 2129-2133
14. Stenzl A., Hoeltl L., and Bartsch G. Fluorescence assisted transurethral resection of bladder tumours: Is it cost effective?. Eur Urol 39 (2001) 31-32
15. Oosterlinck W., Lobel B., Jakse G., Malmstrom P.U., Stockle M., and Sternberg C. European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 41 (2002) 105-112
16. Zaak D., Kriegmair M., Stepp H., et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 57 (2001) 690-694
17. Svatek R.S., Lee D., and Lotan Y. Correlation of office-based cystoscopy and cytology with histologic diagnosis: How good is the reference standard?. Urology 66 (2005) 65-68
18. Witjes J.A., Moonen P.M., and van der Heijden A.G. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective phase II study. Eur Urol 47 (2005) 319-322
19. Loidl W., Schmidbauer J., Susani M., and Marberger M. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: A new approach for bladder cancer detection and surveillance?. Eur Urol 47 (2005) 323-326